Covered recipient · General Payments record
JEREMY H BEIREIS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$829.83
- Reported across 53 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $291.52 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $57.36 | 3 |
| Novo Nordisk AS | $54.07 | 3 |
| Lilly USA, LLC | $39.20 | 2 |
| Daiichi Sankyo Inc. | $35.54 | 2 |
| Merck Sharp & Dohme Corporation | $32.17 | 2 |
| ABBVIE INC. | $30.96 | 2 |
| Astellas Pharma US Inc | $15.48 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.47 | 1 |
| PFIZER INC. | $13.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.68 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103301436 | CMS |
| ABBVIE INC. | $15.28 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103301438 | CMS |
| Amgen Inc. | $26.31 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111527266 | CMS |
| Amgen Inc. | $14.16 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111527268 | CMS |
| Amgen Inc. | $16.89 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111527270 | CMS |
| Astellas Pharma US Inc | $15.48 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139275928 | CMS |
| Daiichi Sankyo Inc. | $16.48 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089398745 | CMS |
| Daiichi Sankyo Inc. | $19.06 | 10/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089398743 | CMS |
| Lilly USA, LLC | $19.40 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135060763 | CMS |
| Lilly USA, LLC | $19.80 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135043932 | CMS |
| Merck Sharp & Dohme LLC | $15.57 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141905856 | CMS |
| Merck Sharp & Dohme LLC | $16.60 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141810810 | CMS |
| Novo Nordisk Inc | $20.55 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096578239 | CMS |
| Novo Nordisk Inc | $14.40 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096604565 | CMS |
| Novo Nordisk Inc | $19.12 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096923360 | CMS |
| PFIZER INC. | $13.27 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131852195 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.47 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137484691 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.